Skip to main content

PET imaging and Theragnostic in neuro-oncology

Edited by:
Silvia Morbelli, PhD, University of Turin, Italy
Nelleke Tolboom, PhD, University Medical Centre Utrecht, Netherlands

Submission Status: Open   |   Submission Deadline: 30 June 2025

This Collection invites researchers to contribute to the growing body of knowledge on PET imaging and theragnostic applications in neuro-oncology. We welcome submissions that explore innovative imaging techniques, the development of new radiopharmaceuticals, and their implications for targeted therapies in brain tumors. The goal is to enhance our understanding of these technologies and their potential to improve patient outcomes in neuro-oncology.

About the collection

Back to top

The integration of Positron Emission Tomography (PET) imaging and theragnostic approaches in neuro-oncology represents a transformative advancement in the diagnosis and treatment of brain tumors. PET imaging provides critical insights into the metabolic and molecular characteristics of tumors, enabling clinicians to tailor therapeutic strategies to individual patients. The development of novel radiopharmaceuticals has further enhanced the specificity and sensitivity of PET imaging, allowing for improved detection and characterization of brain tumors. This Collection aims to explore the latest research and innovations in PET imaging and theragnostic applications, focusing on their implications for patient outcomes in neuro-oncology.

Advancing our collective understanding of PET imaging and theragnostic strategies is crucial for optimizing patient care in neuro-oncology. Recent advances have demonstrated the potential of PET imaging to not only improve diagnostic accuracy but also to guide targeted therapies, thereby enhancing treatment efficacy. The emergence of new radiopharmaceuticals and imaging techniques has opened avenues for personalized medicine, allowing for more precise monitoring of treatment responses. Continued research in this field is essential to refine these technologies and to establish standardized protocols that can be widely adopted in clinical practice.

As research in PET imaging and theragnostics progresses, we can anticipate significant advancements in the future, including the development of novel radiotracers that target specific tumor markers and the integration of artificial intelligence in imaging analysis. These innovations may lead to more accurate prognostic assessments and the ability to predict treatment responses, ultimately improving patient outcomes in neuro-oncology. EJNMMI Reports therefore calls for articles which address research including, but not limited to:

  • Advances in PET Imaging for Brain Tumors
  • Theragnostic Approaches in Neuro-oncology
  • Role of Radiopharmaceuticals in Targeted Therapy
  • Diagnostic Imaging Techniques in Neuro-oncology
  • Molecular Imaging and Personalized Medicine

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system. During the submission process, under the section additional information, you will be asked whether you are submitting to a Collection, please select "PET Imaging and Theragnostic in Neuro-oncology" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.

There are currently no articles in this collection.